Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2012

View Archived Issues

Identification of biological markers to distinguish MCI from early-stage AD

DiaGenic announces improved blood test to detect Alzheimer's disease

Boehringer Ingelheim presents novel B-raf inhibitors

German researchers design new mGlu5 receptor modulators

Hong Kong researchers patent new agents for cancer

Sarepta's lead candidate for Marburg virus improves survival in primates

The Medicines Company patents new agents for thrombotic disorders

Phase III study of brivanib in HCC does not meet primary endpoint

Abbott offers overview of second quarter 2012

Sigma-Tau presents new HSP 90 inhibitors

New metabotropic glutamate receptor antagonists synthesized at Novartis

Novartis highlights achievements of second quarter 2012

Agilent enters biomarker discovery collaboration with Gachon University of Medicine and Science

FDA grants accelerated approval to Onyx' Kyprolis for injection in treatment of multiple myeloma

SEARCH trial shows no overall survival improvement with addition of Tarceva to Nexavar in HCC

EMA committee recommends approval of Adcetris for two lymphoma indications

Yichang Humanwell obtains license to remimazolam in China from Paion

Investigators develop novel ischemia-reperfusion model in human placenta

CHMP recommends conditional approval of crizotinib

Meiji Seika Pharma to discontinue development of schizophrenia drug candidate

Piramal receives clearance in India to conduct P-276 study

EB-101 shows efficacy in animal models of AD

EMA committee recommends approval of first gene therapy

Phase III study in breast cancer begins for novel micellar nanoparticles

FDA approves Afinitor in combination with exemestane in advanced breast cancer

Janssen submits application for new formulation of anti-HIV agent in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...